Novartis AG · SIX:NOVN

Novartis — Investor Day (September 2008)

8 slides from Novartis's investor day presentation, Sep 3, 2008

  1. Slide 1: Germany: Winning in a Transforming Market

    Germany: Winning in a Transforming Market Sandoz Day Helmut Fabry CEO Sandoz Germany September 3, 2008 Sandoz Germany: Steadily expanding leadership Profile Germany sales, in USD bn ƒ #1 in Germany 1.5 ƒ Associates: 4,300 1.3 ƒ Three brands ƒ Headquarters: Holzkirchen ƒ Production and D&R sites 0.8

  2. Slide 2: Winning in a transforming market

    Winning in a transforming market ƒ Flexible and agile organization • Effective • Simple • Efficient ƒ Leverage • Use market leadership for new difficult-to-makes and biosimilars • Build on #1 Hexal brand ƒ Expand and enrich prescription drug portfolio 3 | Sandoz Day | Helmut Fabry | September 3, 200

  3. Slide 3: Dispensing power depends on product segment

    Dispensing power depends on product segment Key dispensing influencer Individual Buying Physician pharmacy groups Brand Product brand Main Special- ties product INN+ Company brand 2008 type Standard Pure products Distribution, price INN Doctor Pharmacy Key sales force sales force accounts 5 | Sandoz

  4. Slide 4: Germany: Agility and flexibility key to success

    Germany: Agility and flexibility key to success Despite high level of … Sandoz is well-prepared for future challenges uncertainty in the market… ƒ Clear #1 in the German generics market ƒ Rebate contracts ƒ Successful integration of Sandoz and Hexal ƒ Stakeholder influence ƒ Leading in rebate contra

  5. Slide 5: Sandoz quick to adapt new business model

    Sandoz quick to adapt new business model Share of SHI1 rebate contract-regulated market (62% of total market) Quarterly development Market share as of June 2008 40 Sandoz Sandoz Group 35% 35 Group Ratiopharm Group 25% 30 Stada Group 17% 25 Ratiopharm Group Mylan 5% 20 Stada Neuraxpharma 1% 15 Group

  6. Slide 6: German leader in difficult-to-make products

    German leader in difficult-to-make products Fentanyl patches ƒ Market share1 29% ƒ Market share growth2 +2 ppt ƒ Number of generic competitors 11 Metoprolol Succinate ƒ Market share1 47% ƒ Market share growth2 +0 ppt ƒ Number of generic competitors 1 Leuprone ƒ Market share1 6% ƒ Market share growth

  7. Slide 7: Strong OTC profile enhances prescription brands

    Strong OTC profile enhances prescription brands Gingium ƒ Market share1 29% ƒ Number of competitors >35 ƒ #2 market segment rank ACC Akut ƒ Market share1 85% ƒ Number of competitors >25 ƒ Clear #1 market segment rank Calcium Sandoz ƒ Market share1 9% ƒ Number of competitors >155 ƒ Top 3 in market se

  8. Slide 8: Winning in a transforming market

    Winning in a transforming market Sandoz Group Germany Winning in a transforming market ƒ Enhance #1 position: ƒ Flexible and agile organization Brand and market share ƒ Preferred business partner ƒ Leverage market leadership ƒ Coverage of every segment • #1 and trusted Hexal brand • Strong company b

Novartis — Investor Day (September 2008) on 6ix